Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of Cumulative Exposure to Ocrelizumab on Memory B‐Cell Repopulation Dynamics in Multiple Sclerosis

11 Jun 2025

Abstract excerpt

OBJECTIVE: Extended interval dosing protocols of B-cell-depleting therapies in multiple sclerosis (MS) are being developed, but intervals between infusions are often arbitrary. We describe total and memory B-cell repopulation dynamics in MS patients on a memory B-cell-guided extended interval dosing ocrelizumab (OCR) protocol. METHODS: OCR was administered on peripheral CD19+ CD27+ memory B-cell repopulation (≥1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Multiple Sclerosis Research Studies
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40497506
DOI: 10.1002/ana.27281

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of Cumulative Exposure to Ocrelizumab on Memory B‐Cell Repopulation Dynamics in Multiple SclerosisPMID 40497506Read ↗

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with OcrelizumabSemantic proximity Read ↗

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity Read ↗

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activitySemantic proximity Read ↗

Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity Read ↗

B cell-extrinsic and intrinsic factors linked to early immune repletion after anti-CD20 therapy in patients with Multiple Sclerosis of African AncestrySemantic proximity Read ↗

Fingolimod alters intrathecal B cell maturation in multiple sclerosis patientsSemantic proximity Read ↗

Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis.Semantic proximity Read ↗

B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple SclerosisSemantic proximity Read ↗

Quantifying MS Progression in the Era of Highly Effective Therapy: Trial Design ImplicationsSemantic proximity Read ↗

Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapySemantic proximity Read ↗

Dynamics of spinal fluid immune cell alterations following cladribine tablet treatment in multiple sclerosisSemantic proximity Read ↗

Longitudinal follow-up of SARS-CoV-2 vaccine- induced antibody responses in patients with multiple sclerosis treated with anti-CD20 therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.